Harrow (HROW) Current Deferred Revenue (2010 - 2026)
Harrow's (HROW) quarterly Current Deferred Revenue came in at $149000.0 in Q1 2026, up 2.76% year-on-year from $145000.0 in Q1 2025, and down 81.09% quarter-over-quarter from $788000.0 in Q4 2025.
Harrow (HROW) Current Deferred Revenue (2010 - 2026) Analysis & Trends
Harrow's Current Deferred Revenue history runs 13 years deep, the most recent figure standing at $149000.0 for Q1 2026.
- On a quarterly basis, Current Deferred Revenue rose 2.76% year-over-year to $149000.0 in Q1 2026; TTM through Mar 2026 was $149000.0, a 2.76% increase from a year earlier, with the FY2025 full-year figure at $788000.0, up 1690.91% from the prior year.
- Current Deferred Revenue declined to $149000.0 in Q1 2026 per HROW's latest filing, from $788000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $788000.0 in Q4 2025 and bottomed at $23000.0 in Q1 2022.
- The 5-year median for Current Deferred Revenue is $115000.0 (2022), against an average of $165882.4.
- Across the five-year window, Current Deferred Revenue surged 3733.33% in 2022 and sank 63.31% in 2025, its largest moves.
- Year by year, Current Deferred Revenue stood at $113000.0 in 2022, then slumped by 33.63% to $75000.0 in 2023, then sank by 41.33% to $44000.0 in 2024, then soared by 1690.91% to $788000.0 in 2025, then plunged by 81.09% to $149000.0 in 2026.
- Per Business Quant, the three latest HROW Current Deferred Revenue figures stand at $149000.0 (Q1 2026), $788000.0 (Q4 2025), and $345000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 149,000.00 |
| Dec 31, 2025 | 788,000.00 |
| Sep 30, 2025 | 345,000.00 |
| Jun 30, 2025 | 91,000.00 |
| Mar 31, 2025 | 145,000.00 |
| Dec 31, 2024 | 44,000.00 |
| Sep 30, 2024 | 137,000.00 |
| Jun 30, 2024 | 248,000.00 |
| Mar 31, 2024 | 112,000.00 |
| Dec 31, 2023 | 75,000.00 |
| Sep 30, 2023 | 153,000.00 |
| Jun 30, 2023 | 132,000.00 |
| Mar 31, 2023 | 67,000.00 |
| Dec 31, 2022 | 113,000.00 |
| Sep 30, 2022 | 115,000.00 |
| Jun 30, 2022 | 83,000.00 |
| Mar 31, 2022 | 23,000.00 |
| Dec 31, 2021 | 16,000.00 |
| Sep 30, 2021 | 3,000.00 |
| Jun 30, 2021 | 56,000.00 |